Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 04:53 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Evaluation of Safety Following Immune Tolerance Induction Treatment With Turoctocog Alfa in Patients With Haemophilia A Following Inhibitor Development in NN7170-4213 Trial
NCT03588741 · Novo Nordisk A/S · PHASE3 · terminated · last registry update 2020-07-07 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The trial was terminated as the participant withdrew from the trial.” | – | Registry record, Novo Nordisk A/S |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against F8 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2021-07-07Results posted on the registry: Bioverativ, a Sanofi company, rFVIIIFc (NCT03093480)
- 2021-05-24Also stopped (terminated): Baxalta now part of Shire, Recombinant antihemophilic factor, plasma/albumin-free method (rAHF-PFM) (NCT01376700)
- 2021-05-14Also stopped (terminated): Baxalta now part of Shire, OBI-1 (NCT01434511)
- 2021-05-10Results posted on the registry: Novo Nordisk A/S, Concizumab + Turoctocog alfa (NCT03196297)
- 2021-05-03Results posted on the registry: Pfizer, Moroctocog-alfa (AF-CC) (NCT04396639)
- 2021-04-15Phase 3 first posted: Zhengzhou Gensciences Inc, Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection (NCT04845399)
- 2021-02-18Phase 3 first posted: Bioverativ, a Sanofi company, efanesoctocog alfa (BIVV001) (NCT04759131)
- 2020-12-17Also stopped (withdrawn): City of Hope Medical Center, FVIII Concentrates + FVIII/VWF concentrates (NCT01051544)
- 2020-11-25Phase 3 first posted: Bioverativ, a Sanofi company, efanesoctocog alfa (BIVV001) (NCT04644575)
- 2020-11-03Results posted on the registry: Bayer, Recombinant Factor VIII (Kovaltry, BAY81-8973) + Recombinant Factor VIII (Kovaltry, BAY81-8973) (NCT01311648)
- 2020-10-08Phase 3 first posted: Takeda, TAK-672 (NCT04580407)
- 2020-10-08Results posted on the registry: The Hospital for Sick Children, Kogenate FS, Advate, or Humate-P, Recombinate, Helixate FS (NCT00717626)
- 2020-09-25Results posted on the registry: Craig Seaman, rFVIII (NCT02586012)
- 2020-09-25Also stopped (terminated): Craig Seaman, rFVIII (NCT02586012)
- 2020-09-24Phase 3 first posted: Emory University, Emicizumab + FEIBA (NCT04563520)
- 2020-08-28Results posted on the registry: Laboratoire français de Fractionnement et de Biotechnologies, Coagulation FVIIa (Recombinant) (NCT02448680)
- 2020-08-13Results posted on the registry: Bioverativ, a Sanofi company, rFVIIIFc (NCT02234323)
- 2020-07-02Phase 3 first posted: Zhengzhou Gensciences Inc, Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection + Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection (NCT04456387)
- 2020-06-16Phase 3 first posted: Hoffmann-La Roche, Emicizumab (NCT04431726)
- 2020-06-16Results posted on the registry: PTC Therapeutics, Ataluren (NCT00947193)
- 2020-06-16Also stopped (terminated): PTC Therapeutics, Ataluren (NCT00947193)
- 2020-05-29Results posted on the registry: University of California, Davis, Wilate (NCT03204539)
- 2020-05-29Also stopped (terminated): University of California, Davis, Wilate (NCT03204539)
- 2020-05-22Results posted on the registry: AbbVie, Depatuxizumab mafodotin + Temozolomide (NCT02343406)
- 2020-04-30Phase 3 first posted: Pfizer, PF-07055480 (giroctocogene fitelparovec): Recombinant AAV2/6 Human Factor VIII Gene Therapy (NCT04370054)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision